Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 12/31/2025

Tratamiento para Infección de Vías Urinarias Complicada

Definición y factores asociados

  • Las infecciones urinarias complicadas ocurren cuando existen factores del huésped o anomalías anatómicas/funcionales del tracto urinario que hacen más difícil la erradicación de la infección en comparación con una infección no complicada, y se asocian con factores como obstrucción en cualquier parte del tracto urinario, presencia de cuerpo extraño, vaciado incompleto de la vejiga, reflujo vesicoureteral, historia reciente de instrumentación, infección en hombres, embarazo, diabetes mellitus, inmunosupresión, infecciones asociadas a la atención sanitaria y aislamiento de organismos productores de BLEE o multirresistentes 1

Espectro microbiano

  • El espectro microbiano es más amplio que en las ITU no complicadas, con mayor probabilidad de resistencia antimicrobiana, y los patógenos más comunes incluyen E. coli, Proteus spp., Klebsiella spp., Pseudomonas spp., Serratia spp. y Enterococcus spp. 1, 2, 3

Tratamiento empírico inicial

  • Se recomienda usar una combinación de amoxicilina más un aminoglucósido, una cefalosporina de segunda generación más un aminoglucósido, o una cefalosporina intravenosa de tercera generación 3, 4
  • Opciones específicas para terapia parenteral incluyen ciprofloxacino 400 mg cada 12 horas, cefotaxima 2 g cada 8 horas, ceftriaxona 1-2 g cada 24 horas, cefepime 1-2 g cada 12 horas, piperacilina/tazobactam 2.5-4.5 g cada 8 horas, gentamicina 5 mg/kg cada 24 horas y amikacina 15 mg/kg cada 24 horas 1, 2

Tratamiento para patógenos resistentes

  • Para infecciones por Enterobacterias resistentes a carbapenémicos, se recomiendan ceftazidima/avibactam 2.5 g IV cada 8 horas, meropenem/vaborbactam 4 g IV cada 8 horas e imipenem/cilastatina/relebactam 1.25 g IV cada 6 horas 5, 6
  • Para infecciones por Pseudomonas aeruginosa resistente a carbapenémicos, se recomiendan piperacilina o piperacilina/tazobactam, ceftazidima o cefepime, ciprofloxacino o levofloxacino y amikacina 4

Duración del tratamiento

  • La duración del tratamiento para infecciones urinarias complicadas es de 7-14 días, y para hombres cuando no se puede excluir prostatitis es de 14 días 2

Manejo integral

  • Es obligatorio el manejo adecuado de la anomalía urológica o del factor subyacente que complica la infección, y se debe realizar un cultivo de orina y pruebas de susceptibilidad, ajustando la terapia empírica inicial según los resultados 1, 2

Treatment of Complicated Urinary Tract Infections

Introduction to Complicated Urinary Tract Infections

  • The Infectious Diseases Society of America recommends monotherapy with aminoglycosides for urinary tract infections, particularly when there is prior resistance to fluoroquinolones 7

Treatment Options for Complicated Urinary Tract Infections

  • Ceftazidima/avibactam 2.5 g IV every 8 hours is recommended for the treatment of complicated urinary tract infections caused by carbapenem-resistant Enterobacteriaceae (CRE), with a duration of 5-7 days 7
  • Meropenem/vaborbactam 4 g IV every 8 hours is also recommended for the treatment of complicated urinary tract infections caused by CRE 7
  • Imipenem/cilastatina/relebactam 1.25 g IV every 6 hours is another option for the treatment of complicated urinary tract infections caused by CRE 7
  • Plazomicina 15 mg/kg IV every 12 hours is specifically recommended for complicated urinary tract infections caused by CRE, with evidence of lower mortality (24% vs 50%) and lower acute kidney injury (16.7% vs 50%) compared to colistin-based regimens 8

Duration of Treatment

  • The recommended duration of treatment is 7-14 days, with specific considerations for complicated urinary tract infections, including 7-10 days for patients who are hemodynamically stable and afebrile for at least 48 hours 7
  • For infections caused by CRE, the duration of treatment is 5-7 days 7

Treatment of Complicated Urinary Tract Infections with Resistant Organisms

Initial Empiric Therapy Selection for Resistant Organisms

  • The American Urological Association recommends avoiding single-dose aminoglycoside therapy for complicated UTIs, as it is only appropriate for simple cystitis due to CRE 9
  • The Infectious Diseases Society of America suggests not treating asymptomatic bacteriuria in non-pregnant patients 10

Risk Stratification for Resistant Organisms

  • Patients with known colonization with ESBL or CRE organisms are at higher risk for multidrug-resistant pathogens, and empiric therapy should include broader-spectrum agents like piperacillin-tazobactam or carbapenems until susceptibilities are known 9

Treatment for Carbapenem-Resistant Enterobacteriaceae (CRE)

  • The European Society of Clinical Microbiology and Infectious Diseases recommends using newer beta-lactam/beta-lactamase inhibitor combinations, such as ceftazidime-avibactam, meropenem-vaborbactam, or imipenem-cilastatin-relebactam, for 5-7 days for CRE infections 9
  • Plazomicin 15 mg/kg IV every 12 hours is particularly advantageous with lower mortality and reduced acute kidney injury compared to colistin-based regimens for CRE infections 9

Imipenem Dosing for Complicated Urinary Tract Infections

Standard Dosing Regimen

  • The FDA-approved dosing provides flexibility based on infection severity, with the 1000 mg every 8 hours regimen being the most commonly cited in guidelines for healthcare-associated infections, as recommended by the World Journal of Emergency Surgery 11, 12

When to Use Imipenem for UTIs

  • Reserve imipenem for specific high-risk scenarios, including healthcare-associated complicated UTIs with risk factors for multidrug-resistant organisms (MDROs), recent antibiotic exposure, nursing home residents with indwelling catheters, post-operative intra-abdominal infections extending to urinary tract, immunocompromised patients, and critically ill patients with healthcare-associated infections, as suggested by the World Journal of Emergency Surgery 11, 12

Alternative Carbapenem Options for UTIs

  • Newer carbapenem combinations, such as imipenem/cilastatin/relebactam 1.25 g IV every 6 hours, offer advantages for carbapenem-resistant Enterobacteriaceae (CRE), as demonstrated in the RESTORE-IMI-1 and TANGO-II trials, according to the Journal of Microbiology, Immunology and Infection 13

Combination Therapy Considerations

  • For high-risk enterococcal coverage, add ampicillin 2 g IV every 6 hours if not using imipenem, as imipenem already covers ampicillin-susceptible enterococci, as recommended by the World Journal of Emergency Surgery 11, 12

Treatment of Resistant Urinary Tract Infections

Principles of Management

  • The American Urological Association recommends obtaining a urine culture and antibiogram before starting antimicrobial therapy in patients with recurrent or resistant urinary tract infections, to confirm the diagnosis, identify resistance patterns, and adjust empirical therapy accordingly 14, 15
  • The Infectious Diseases Society of America suggests that microbiological documentation is essential to distinguish between true infection and colonization, and to guide targeted antibiotic therapy 16, 17

Treatment Algorithm by Resistance Type

  • For complicated urinary tract infections caused by carbapenem-resistant Enterobacteriaceae (CRE), treatment options include ceftazidime-avibactam 2.5g IV every 8 hours for 5-7 days, with a strength of evidence rated as high 16
  • For uncomplicated urinary tract infections caused by vancomycin-resistant Enterococcus (ERV), treatment options include fosfomycin 3g PO single dose, with a cure rate of 88.1% 16, 17

Duration of Treatment

  • The standard duration of treatment for complicated urinary tract infections is 7-14 days, with a strength of evidence rated as moderate 14, 15
  • For CRE infections, the recommended duration is 5-7 days, with a strength of evidence rated as low 16

Advertencias Críticas

  • The American College of Obstetricians and Gynecologists recommends against treating asymptomatic bacteriuria, except in pregnant women or patients undergoing invasive urological procedures, due to the risk of increasing antimicrobial resistance without clinical benefit 14, 15

Treatment of Complicated Urinary Tract Infections

Introduction to Guideline Recommendations

  • The American Urological Association recommends against treating asymptomatic bacteriuria in non-pregnant patients with catheters or multiple comorbidities, as this increases resistance and recurrence rates 18

Special Considerations for Patient Populations

  • The Infectious Diseases Society of America suggests that all urinary tract infections in male patients are complicated and should be treated for a minimum of 14 days, as prostatitis cannot be excluded initially 18
  • The Centers for Disease Control and Prevention recommend that catheter-associated urinary tract infections should only be treated if symptomatic, and the catheter should be removed or replaced when possible before or during treatment 18

Ceftazidime‑Avibactam Dosing for Complicated Klebsiella Urinary Tract Infections

Dosage Recommendations

  • For adults with complicated urinary tract infections caused by Klebsiella spp., administer ceftazidime‑avibactam 2.5 g (2 g ceftazidime + 0.5 g avibactam) intravenously every 8 hours, infused over 2 hours, for a typical course of 5–7 days. 19, 20

Treatment Duration

  • The total therapy should last 7–14 days; a 7‑day course is appropriate when the patient shows rapid clinical improvement, whereas a 14‑day course is advised for slower response or when prostatitis cannot be excluded in male patients. 19, 20

Therapeutic Considerations

  • Single‑dose aminoglycoside therapy should not replace a full ceftazidime‑avibactam regimen in complicated UTIs; aminoglycoside monotherapy is reserved only for uncomplicated cystitis caused by carbapenem‑resistant Enterobacterales. 19

REFERENCES

← Return to Home